More recently, the inhibition of MCP-1/CCL2 using neutralizing antibodies or downstream receptor blockade has been demonstrated to reduce albuminuria and inflammation in rodent DKD models [31,55]. The gene discussed is CCL2; the disease is diabetic kidney disease.